Shandong Sito Bio-technology Co

Shandong Sito Bio-technology Co FCF per Share

The Free Cash Flow per Share of Shandong Sito Bio-technology Co (300583.SZ) as of Nov 3, 2026 is 0.39 CNY. In the previous year, Free Cash Flow per Share was 0.63 CNY — a change of -37.89% (lower).

FCF per Share

0.39CNY

YoY

-37.89%

Last updated:

Free Cash Flow per Share of Shandong Sito Bio-technology Co is 2025 0.39 CNY. Free Cash Flow per Share of Shandong Sito Bio-technology Co was 2024 0.63 CNY. It decreases by -37.89% lower compared to the previous year.

The Shandong Sito Bio-technology Co FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2018
-3.35 CNY
Jan 1, 2019
-0.92 CNY
Jan 1, 2020
0.07 CNY
Jan 1, 2021
-0.94 CNY
Jan 1, 2022
0.01 CNY
Jan 1, 2023
-0.99 CNY
Jan 1, 2024
0.63 CNY
Jan 1, 2025
0.39 CNY
The Shandong Sito Bio-technology Co FCF per Share history
YEARFCF per ShareYoY
0.39CNY-37.89%
0.63CNY-164.26%
-0.99CNY-10,976.10%
0.01CNY-100.97%
-0.94CNY-1,441.64%
0.07CNY-107.63%
-0.92CNY-72.70%
-3.35CNY+791.12%
-0.38CNY+6.98%
-0.35CNY+3.39%
-0.34CNY+24.29%
-0.27CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shandong Sito Bio-technology Co Stock analysis

What does Shandong Sito Bio-technology Co do? Shandong Sito Bio-technology Co., Ltd. generates revenue through three product segments. The Steroid Raw Materials segment produces steroid raw materials like androstenedione and 9-hydroxyandrostenedione using genetic engineering and microbial transformation technology. The Steroidal Finished Drug segment and Non-Steroidal Finished Drug segment are operated via its subsidiary, offering finished pharmaceutical products. The company's primary customers are pharmaceutical manufacturers requiring raw materials and finished drugs for further processing. The Steroid Raw Materials segment focuses on manufacturing key compounds such as androstenedione, hydroxyprogesterone, and 9-hydroxyandrostenedione. These materials are essential for the production of various steroid-based pharmaceuticals. The Steroidal Finished Drug segment provides ready-to-use pharmaceutical products, while the Non-Steroidal Finished Drug segment offers non-steroid alternatives, targeting different medical needs. Shandong Sito serves pharmaceutical companies that need raw materials for steroid-based drugs and finished drugs for distribution. The Steroid Raw Materials segment supplies critical inputs for steroid pharmaceutical production, while the Steroidal and Non-Steroidal Finished Drug segments cater to end-market demand for completed pharmaceutical products. The company's operations are centered around biotechnology-driven manufacturing of pharmaceutical ingredients and finished drugs. Shandong Sito Bio-technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shandong Sito Bio-technology Co stock

Free Cash Flow per Share of Shandong Sito Bio-technology Co is 0.39 CNY in 2025.

Free Cash Flow per Share of Shandong Sito Bio-technology Co changed from 0.63 CNY to 0.39 CNY, representing a -37.89% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share Shandong Sito Bio-technology Co since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Shandong Sito Bio-technology Co

All Key Metrics — Shandong Sito Bio-technology Co